Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561621 | 1.00 | MAOB (0.56) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL1547206 | 0.84 | MAOB (0.65) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL7082856 | 0.84 | CYP19A1 (0.42) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL29987845 | 0.83 | CHRNA7 (0.47) | MEN1KMT2APKMCYP19A1CYP11B1 | |
| SCHEMBL4234692 | 0.83 | CHRNA7 (0.47) | MEN1KMT2APKMCYP19A1CYP11B1 | |
| SCHEMBL25382254 | 0.82 | AGXT (0.46) | MAOBMAPTRAB9AMEN1KMT2A | |
| SCHEMBL18429631 | 0.82 | APP (0.59) | MEN1KMT2AKDM4EIDO1 | |
| SCHEMBL11182657 | 0.82 | NPC1 (0.47) | MAOBRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3365264 | 0.82 | MEN1 (0.60) | MAOBMEN1KMT2ACXCR2KDM4E | |
| SCHEMBL25381620 | 0.82 | RAB9A (0.59) | MAOBGAAMAPTMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-07 | — | — | US | disclosed |
| EP-4169916-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| CN-115955968-A | Carbohydrazone acyldinitrile compounds comprising at least two aryl or heteroaryl groups connected by a novel linker and uses thereof | 韩国科学技术研究院 | 2023-04-11 | — | — | CN | disclosed |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-12-29 | — | — | US | disclosed |
| US-11325892-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-10 | — | — | US | disclosed |
| CN-109689652-B | Fused heterocyclic derivative, preparation method and medical application thereof | 北京诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021256902-A1 | CARBONOHYDRAZONOYL DICYANIDE COMPOUND INCLUDING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY NOVEL LINKER, AND USE THEREOF | 한국과학기술연구원 | 2021-12-23 | — | — | WO | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| CN-1158281-C | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | ��һ��������ҩ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| US-6541480-B2 | Controlling cytokines | SUNTORY LIMITED (JP) | 2003-04-01 | — | — | US | disclosed |
| CN-1391563-A | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | CN | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| CN-1239478-A | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LTD (JP) | 1999-12-22 | — | — | CN | disclosed |
| EP-0958297-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999007704-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325892-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | MAOB 1488/4885GAA 1775/4885MAPT 2698/4885 |
| US-20230278965-A1 | NOVEL CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS COMPRISING 2 OR MORE ARYL OR HETEROARYL CONNECTED VIA LINKER AND USE THEREOF | AADAC, CBR3, MTCL3 | MAOB 976/4885GAA 3465/4885MAPT 2830/4885 |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | MAOB 1488/4885GAA 1775/4885MAPT 2698/4885 |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | MAOB 178/4885GAA 1154/4885MAPT 4826/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | MAOB 85/4885GAA 1775/4885MAPT 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.